TG Therapeutics stock saw a welcome improvement to its Relative Strength (RS) Rating on Thursday, rising from 87 to 93.
When looking for the best stocks to buy and watch, be sure to pay attention to relative price strength. IBD's unique rating identifies market leadership with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.
Decades of market research reveals that the top-performing stocks often have an RS Rating of at least 80 as they begin their biggest runs.
See How IBD Helps You Make More Money In Stocks
Is TG Therapeutics Stock A Buy?
TG Therapeutics stock has been rallying off the bottom of a steep base. While TG Therapeutics is not near an ideal entry right now, see if it is able to form and break out of a proper base. Read "Looking For The Next Big Stock Market Winners? Start With These 3 Steps" for more tips.
The biotech company showed 0% earnings growth in the latest quarterly report, while sales growth came in at 184,144%.
TG Therapeutics stock earns the No. 42 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, Neurocrine Biosciences and Immunogen are among the top 5 highly rated stocks within the group. For more industry news, check out "Biotech And Pharmaceutical Industry And Stock News."
